GLP1-RT is a synthetic peptide classified as a GGG tri-agonist, targeting glucagon-like peptide-1 (GLP-1), gastric inhibitory polypeptide (GIP), and glucagon receptors. Laboratory research involving GLP1-RT investigates its multifaceted receptor interactions and their roles in metabolism, particularly related to energy expenditure, appetite modulation, and lipid metabolism. Studies indicate that GLP1-RT may impact basal metabolism and energy utilization through distinct receptor-mediated pathways.

Scientific investigations continue to explore GLP1-RT’s potential roles in obesity management, metabolic health, and appetite control in controlled laboratory environments.

Important Notice: This product is intended strictly for research purposes only. It is not approved by the FDA and is not intended for human or animal consumption, nor for diagnostic, therapeutic, or clinical applications. Usage of GLP1-RT outside laboratory research settings violates sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. §§ 355(a) and 331(d).

Product Specifications:

• Purity: ≥99% (HPLC verified)
• Formulation: Lyophilized powder
• Molecular Formula: C₂₂₃H₃₄₃F₃N₄₆O₇₀
• Molecular Weight: 4731.33 g/mol
• CAS Number: 2381089-83-2
• Synonyms: Retatrutide, LY3437943, GGG tri-agonist, GLP-1/GIP/Glucagon receptor agonist
• PubChem CID: 474492335